BPGbio has entered a collaborative agreement with Grupo Terralpe for the commercialisation of its prostate cancer diagnostic test, pstateDx, in Mexico.
The pstateDx test is claimed to be the first diagnostic product discovered leveraging BPGbio’s artificial intelligence-driven platform, Interrogative Biology.
Go deeper with GlobalData
Grupo Terralpe CEO Javier Prieto said: “BPGbio’s pstateDx test will enhance our healthcare offering and we are eager to bring the benefits of this novel prostate cancer diagnostic test to Mexico.”
The non-prostate-specific antigen-based molecular diagnostic blood test helps measure filamin A, a crucial biological prostate cancer driver.
Clinicians can use the risk score offered by the test for differentiating between benign prostatic hyperplasia (BPH) and aggressive prostate cancer at the initial screening time.
It was estimated that roughly 2.3 million men in Mexico had been diagnosed with BPH, according to a study published in 2019.
BPGbio CEO and president Niven Narain said: “Through our strategic partnership, Grupo Terralpe will bring the pstateDx test, BPGbio’s novel prostate cancer test to Mexico in an effort to improve clinical decision support for patients with elevated PSA levels who may have prostate cancer.
“We believe that this test will reduce the need for invasive biopsies and their associated risks and costs in patients with BPH.”
BPGbio is seeking business prospects in various countries to expand the reach of its diagnostic technology.
The pstateDx test is currently unavailable for commercial use within the US.
